The earnings call highlighted significant achievements such as the third FDA approval and strong market leadership in GA with SYFOVRE. However, these positives were balanced by challenges related to high free goods usage impacting revenue and issues with co-pay assistance funding. While the company is in a strong financial position and shows confidence in future growth, the immediate revenue impact from free goods and funding challenges presents a balanced outlook.

Company Guidance -

Q3 2025

In the second quarter of 2025, Apellis Pharmaceuticals reported total revenues of $178 million, with SYFOVRE contributing $151 million and EMPAVELI $21 million, marking a 5% increase in EMPAVELI's revenue quarter-over-quarter. SYFOVRE injections grew by 6% quarter-over-quarter, totaling over 95,000 doses, but revenue was impacted by $13 million due to high utilization of free goods. SYFOVRE maintained its market leadership with over 60% market share and 55% of new patient starts. Apellis also received a $275 million cash payment from Sobi through a capped royalty purchase agreement for Aspaveli. Operating expenses were reduced to $212 million from $229 million in the same quarter last year, with expectations to maintain 2025 expenses in line with 2024. The company ended the quarter with $370 million in cash and anticipates this, alongside future product sales, will fund them to sustainable profitability.

Third FDA Approval in Four Years

Apellis Pharmaceuticals received FDA approval for a label expansion of EMPAVELI, marking their third FDA approval in four years. This approval allows treatment for C3 myelopathy and primary immune complex membranoproliferative glomerulonephritis for patients 12 years and older.

Steady Growth in SYFOVRE Demand

SYFOVRE revenues reached $151 million with a 6% quarter-over-quarter growth in total injections. SYFOVRE holds over 60% market share in geographic atrophy (GA) and is the clear market leader in this segment.

Aspaveli Capped Royalty Purchase Agreement

Apellis gained operational flexibility through a $275 million cash payment upfront from Sobi for 90% of future ex-U.S. Aspaveli royalties up to a cap, highlighting confidence in growth potential for rare kidney diseases.

Strong Financial Position

The company ended the quarter with $370 million in cash and cash equivalents. Combined with future product sales, this is expected to fund the business to sustainable profitability.

Apellis Pharmaceuticals (APLS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

APLS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	1.60 / -	-0.46	―	―	―
Jul 31, 2025	2025 (Q2)	-0.47 / -0.33	-0.3	-10.00% (-0.03)
May 07, 2025	2025 (Q1)	-0.34 / -0.74	-0.54	-37.04% (-0.20)
Feb 28, 2025	2024 (Q4)	-0.37 / -0.29	-0.73	60.27% (+0.44)
Nov 05, 2024	2024 (Q3)	-0.29 / -0.46	-1.17	60.68% (+0.71)
Aug 01, 2024	2024 (Q2)	-0.31 / -0.30	-1.02	70.59% (+0.72)
May 07, 2024	2024 (Q1)	-0.48 / -0.54	-1.56	65.38% (+1.02)
Feb 27, 2024	2023 (Q4)	-0.73 / -0.73	-1.5	51.33% (+0.77)
Nov 01, 2023	2023 (Q3)	-0.99 / -1.17	-1.75	33.14% (+0.58)
Jul 31, 2023	2023 (Q2)	-1.36 / -1.02	-1.46	30.14% (+0.44)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

APLS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$19.00	$22.34	+17.58%
May 07, 2025	$19.12	$17.99	-5.91%
Feb 28, 2025	$26.00	$25.15	-3.27%
Nov 05, 2024	$28.56	$28.08	-1.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Apellis Pharmaceuticals Inc (APLS) report earnings?

Apellis Pharmaceuticals Inc (APLS) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Apellis Pharmaceuticals Inc (APLS) earnings time?

Apellis Pharmaceuticals Inc (APLS) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is APLS EPS forecast?

APLS EPS forecast for the fiscal quarter 2025 (Q3) is 1.61.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing